Identification of Protein Kinases Required for NF2 Signaling
Abstract
The purpose of this concept award grant is to uncover potential drug targets for treatment of Neurofibromatosis type 2 (NF2). We planned a synthetic lethal screen using RNAi technology to uncover protein kinases and phosphates that are specifically required for the survival of NF2-null cells. We also obtained and reformatted a murine siRNA library against all known protein kinases and phosphatases. We also obtained NF2flox/flox mouse embryo fibroblasts and used Cre recombinase to convert these to a NF24-genotype. We then tested a large number of transfection method worked well on the mouse embryo fibroblasts. We then obtained a library of bioactive chemicals and carried out a screen for synthetic lethality. This screen revealed that an inhibitor of the hedgehog pathway (cyclopamine) an inhibitor of Src-Family protein kinases (damnacanthal, as well as PP1 PP2 and tyrphostin) and an agonist of the constitutive androstane receptor (CITGO) all were selectively toxic to NF24-cells. These findings provided the basis for obtaining a grant from the Children's Tumor Foundation.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 01, 2007
- Accession Number
- ADA494392
Entities
People
- Jonathan Chernoff
Organizations
- Fox Chase Cancer Center